Literature DB >> 16162100

The effect of inadequate in situ perfusion in the non heart-beating donor.

Muhammed A Gok1, Aftab A Bhatti, John Asher, Ajay Gupta, Brian K Shenton, Helen Robertson, Naeem A Soomro, David Talbot.   

Abstract

In situ aortic perfusion in the nonheart-beating donors (NHBD) is an important procedure to reduce primary warm ischaemic injury prior to formal donor organ retrieval. It allows an interim period to obtain donor family consent and theatre preparation. This study describes our experience of inadequate aortic perfusions resulting from difficult aortic cannulations and associated adverse outcome despite reasonable viability tests. Since 1998, all NHBD in our institution are perfused in situ using a double balloon triple lumen (DBTL) catheter inserted through a femoral artery cut-down procedure. The DBTL catheter is positioned with distal occlusive balloon at the aortic bifurcation using the "pull-back" technique, the proximal occlusive balloon lies above the renal arteries. This provides selective aortic perfusion in particular the kidneys. Venous decompression using a femoral vein catheter enables a "two-way infusion system". Pre-transplant viability status of retrieved kidneys is determined by measuring pressure/resistance characteristics to the flow and biochemical markers for ischaemic injury. There were 90 NHBD renal transplants performed from 72 donors. Three renal transplants were carried out from three donors of ineffective in situ perfusion secondary to cannulation difficulties. Femoral cannulation was difficult as a result of extensive atherosclerosis of donor vessels. The comparison of allograft outcome from effective and ineffective in situ perfusion of donors showed high rate of primary nonfunction (PNF) from ineffective perfusion (chi-squared, P < 0.0001). The cases demonstrated poor outcome from ineffective perfusion related to the cannulation difficulties. Therefore a strict policy should be taken in cases where aortic cannulation and perfusion is inadequate, despite pretransplant assessment. In these circumstances, the primary warm ischaemia time should be extended to include this period of ineffective perfusion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16162100     DOI: 10.1111/j.1432-2277.2005.00164.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  6 in total

1.  Modification of a biventricular assist device to facilitate preservative infusion and organ recovery in a nonheart-beating donor.

Authors:  Ron Angona; Peter Abt; Duraid Younan; Todd Massey; Michael Marvin; Randeep Kashyap; Dan Richards; Karen Jones; James Queschenbach; Martin Zand; Ashok Jain; Mark Orloff; Adel Bozorgzadeh
Journal:  J Extra Corpor Technol       Date:  2006-06

2.  The use of ex-vivo normothermic perfusion for the resuscitation and assessment of human kidneys discarded because of inadequate in situ perfusion.

Authors:  Sarah A Hosgood; A D Barlow; J Dormer; M L Nicholson
Journal:  J Transl Med       Date:  2015-10-16       Impact factor: 5.531

3.  A Single-center Experience of Kidney Transplantation from Donation after Circulatory Death: Challenges and Scope in India.

Authors:  S Singh; S Kumar; S Dasgupta; D B Kenwar; M Rathi; A Sharma; H S Kohli; V Jha; K L Gupta; M Minz
Journal:  Indian J Nephrol       Date:  2017 May-Jun

4.  Successful Transplantation of Human Kidneys Deemed Untransplantable but Resuscitated by Ex Vivo Normothermic Machine Perfusion.

Authors:  S A Hosgood; K Saeb-Parsy; M O Hamed; M L Nicholson
Journal:  Am J Transplant       Date:  2016-07-13       Impact factor: 8.086

5.  Comparative Analysis of Risk Factors in Declined Kidneys from Donation after Brain Death and Circulatory Death.

Authors:  Zinah Zwaini; Meeta Patel; Cordula Stover; John Dormer; Michael L Nicholson; Sarah A Hosgood; Bin Yang
Journal:  Medicina (Kaunas)       Date:  2020-06-26       Impact factor: 2.430

6.  Importance and limits of ischemia in renal partial surgery: experimental and clinical research.

Authors:  Fernando P Secin
Journal:  Adv Urol       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.